Diffuse intrinsic pontine gliomas
Drug research and approvals for diffuse intrinsic pontine gliomas: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 32 studies of diffuse intrinsic pontine gliomas are recruiting on ClinicalTrials.gov, and Health Canada has authorized 6 drug trials for it since 2013.
- Recruiting worldwide: 32
- Trials authorized in Canada: 6
- FDA orphan approvals: 0
- EU medicines: 0
- Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine…NCT07680439 · Phase 2 · BrainChild Bio, Inc · starts Sep 4, 2026
- NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High…NCT07664176 · Phase 1 · Children's National Research Institute · starts Sep 1, 2026
- A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic…NCT07589257 · Phase 2 · Guangzhou Virotech Pharmaceutical Co., Ltd. · starts May 7, 2026
- Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic…NCT07584499 · Phase 1 · Sun Yat-sen University · starts May 30, 2026
- Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After…NCT07076498 · Phase 1 · M.D. Anderson Cancer Center · starts Apr 23, 2026
- ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade GliomasNCT06838676 · Phase 2 · Nationwide Children's Hospital · starts Jul 10, 2025
- Atovaquone Combined With Radiation in Children With Malignant Brain TumorsNCT06624371 · Phase 1 · Emory University · starts Mar 28, 2025
- Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and SarcomasNCT06465199 · Phase 1 / Phase 2 · Milton S. Hershey Medical Center · starts May 13, 2026
- Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK FusionNCT06333899 · Early Phase 1 · Nationwide Children's Hospital · starts Aug 3, 2025
| Apr 5, 2024 | A multi-part, phase 1, multi-center, open-label, plus expansion clinical trial of an off-the-shelf neo-antigen heat shock protein vaccine (rhsc-dipgvax) in…Rhsc-dipgvax / Zalifrelimab / Balstilimab | Ann and Robert H. Lurie Children's Hospital of Chicago | Pending |
| Jul 6, 2023 | A pilot study of safety, tolerability, and immunological effects of survaxm in pediatric patients with progressive or relapsed medulloblastoma, high grade…Survaxm / Leukine | Childrens Oncology Group | Ongoing |
| Oct 4, 2022 | A phase I study of savolitinib in recurrent, progressive, or refractory medulloblastoma, high-grade glioma, diffuse intrinsic pontine glioma, and CNS tumors…Savolitinib | Pediatric Brain Tumour Consortium | Closed |
| Oct 29, 2021 | A safety and feasibility study to evaluate blood brain barrier disruption using mr-guided focused ultrasound in combination with doxorubicin in treating…Definity (perflutren) / Doxorubicin | Insightec | Pending |
| Oct 24, 2019 | H3.3k27m specific peptide vaccine combined with poly-iclc for the treatment of newly diagnosed HLA-A2+H3.3k27m positive diffuse intrinsic pontine glioma (DIPG)…H3.3K27M peptide vaccine, K27M/TT peptide / Hiltonol (poly-iclc) / Montanide… | Pacific Pediatric Neuro-Oncology Consortium | Pending |
| Aug 29, 2013 | Advl1217, a phase 1 study of MK-1775 (ind#116459) concurrent with local radiation therapy for the treatment of newly diagnosed children with diffuse intrinsic…MK-1775 | Childrens Oncology Group | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA